Anti-Biofilm Therapy for Chronic UTI | Prof. Begoña Heras and Dr. Jason Paxman with Live UTI Free

Anti-Biofilm Therapy for Chronic UTI | Prof. Begoña Heras and Dr. Jason Paxman with Live UTI Free

If you've been stuck in a cycle of recurrent UTIs that antibiotics can't seem to clear, this episode is for you. Melissa sits down with Professor Bogoña Heras and Dr. Jason Paxman, structural biologists from La Trobe University in Australia and co-founders of BioBreak Therapeutics. They share the science behind a groundbreaking anti-biofilm antibody therapy designed specifically for chronic and recurrent UTIs. Unlike antibiotics, this approach doesn't kill bacteria directly. Instead, it dismantles the protective biofilm structures that allow bacteria like uropathogenic E. coli to hide, persist, and resist treatment. With new grant funding secured and preclinical research underway, human trials could be on the horizon within two years.  Key Takeaways 1. Biofilms are the missing piece of the chronic UTI puzzle. Bacteria use a surface protein called antigen 43 to stick together and hide inside the bladder. BioBreak's therapy dismantles this structure, removing the protective coating so the immune system and antibiotics can clear the infection. 2. This therapy is designed for people who have run out of options. It targets chronic and recurrent UTI, including multi-antibiotic resistant cases. It may also work as a monotherapy for people who can no longer tolerate antibiotics at all. 3. Patient testimonials helped make this research happen. Over 350 stories from the Live UTI Free and Chronic UTI Australia communities supported BioBreak's successful grant application and are now shaping how the clinical trials will be designed. Links & Resources * BioBreak Therapeutics: hbsbiobreak.com [https://biobreak.org/] * Chronic UTI Australia: chronicutiaustralia.org.au [https://chronicutiaustralia.org.au] Want to learn more about urinary health? Visit LiveUTIFree.com [http://liveutifree.com/] for expert articles on the latest research, or check out our YouTube channel [https://www.youtube.com/@LiveUTIFree] for a video format.

Why Standard UTI Tests Fail & What Immunotherapy Could Change | Dr. Malcolm Starkey with Live UTI Free

Standard urine cultures have dominated UTI diagnosis for over 70 years, yet they were never designed for this purpose. In this episode, Melissa speaks with Dr. Malcolm Starkey, a scientist at Monash University who leads the Urinary Tract Disease Research Group, about why current testing misses infections, how the urinary microbiome connects to your gut and vagina, and why immunotherapy, not just antibiotics, may be the future of chronic UTI treatment. Dr. Starkey explains the science behind diagnostic gaps, the role of Type 2 immunity in bladder health, and what personalized medicine could look like for recurrent infection. If you’ve received a negative test despite clear symptoms, this episode explains why that happens and what researchers are doing to change it. The gap between what patients experience and what standard tests detect reflects a fundamental limitation in how UTIs are diagnosed. Research is moving toward understanding the immune response, not just the bacteria, and that shift could change everything. What You’ll Learn * Why standard urine cultures fail to detect many infections: The 100,000 CFU threshold came from a 1950s pregnancy study, not UTI diagnosis. Bacteria hide inside bladder cells. Labs exclude samples with epithelial cells, treating a sign of infection as contamination. * How your gut, vagina, and bladder microbiomes connect: Uropathogenic E. coli bloom in your gut, then colonize your urethra. Protective Lactobacilli in your vagina help, but what matters most is how your immune system responds to these bacteria. * Why immunotherapy could work when antibiotics alone don’t: Antibiotics kill bacteria. Immunotherapy restores immune balance. Your bladder prioritizes repair over immune memory, unlike your kidneys. Type 2 immunity, stronger in women, may be dysregulated in chronic UTI. Existing asthma treatments could be repurposed to address this. Resources & Links * Monash University Urinary Tract Disease Research Group [https://www.monash.edu/medicine/translational/immunology/research/urinary-tract-disease] * Bladder and Kidney Health Discovery Program [https://www.monash.edu/medicine/translational/research/bladder-and-kidney-health]  * Chronic UTI Australia [https://www.chronicutiaustralia.org.au] (provides clinician information for Australian residents)

EAT-UP Trial: Extended Antibiotic Treatment for Chronic UTI | Dr. Kiren Gill and Dr. Harry Horsley with Live UTI Free (LUF)

A clinical trial that defines chronic UTI and tests a treatment protocol designed around it has been a long time coming. In this episode of the Live UTI Free podcast, host Dr. Melissa Kramer sits down with Dr. Kiran Gill and Dr. Harry Horsley to talk through the EAT-UP trial, a new UK-based phase 2 randomised controlled trial investigating extended full-dose antibiotics combined with methenamine hippurate (Hiprex) for chronic UTI. Dr. Kiran Gill is a consultant urogynaecologist at the Whittington Hospital and a clinical academic at University College London, and co-chief investigator on EAT-UP alongside Professor Rajvinder Khasriya. Dr. Harry Horsley is principal investigator and scientific lead, and co-leads the Bladder Infection and Immunity Group (BIIG) at UCL, where he has been researching recurrent and chronic UTI for over 15 years. Together, Melissa, Kiran, and Harry walk through how recurrent UTI and chronic UTI are defined, and why the lack of NHS guidelines for chronic UTI leaves patients misdiagnosed with conditions such as painful bladder syndrome (interstitial cystitis), overactive bladder, or the genitourinary syndrome of menopause. The conversation also covers the two trial arms: extended full-dose antibiotics plus methenamine hippurate compared to the current NICE-recommended low-dose prophylaxis informed by the ALTAR study. They explain why fresh urine microscopy is being used as the primary endpoint instead of standard MSU culture alone, the perineal swab approach to tracking antimicrobial resistance, who is eligible for the trial, and how to access screening at the five UK trial sites (Whittington, UCLH, Guy’s and St Thomas’, Manchester St Mary’s, and Newcastle). Recruitment closes August 2027, with first results expected in early 2028. Key Takeaways 1. EAT-UP is the first RCT built around a clinical definition of chronic UTI. It defines the condition as continuous daily urinary symptoms lasting more than three months, with acute flares in between. 2. The trial looks at the host response, not just the bacteria. Fresh urine microscopy checks for white blood cells as a sign of an immune response, giving same-day results instead of a two- to three-day wait for culture. 3. The design reflects what patients actually need. Clinicians choose the antibiotic based on tolerability and history. D-mannose, cranberry, and vaginal oestrogen are allowed, flares are managed with rescue therapy, and travel is reimbursed up to £45. Links and Resources Mentioned * Learn more about EAT-UP Trial: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbDlDS3gtWWFTdXRhRk5iUHJzYkJjY0FNMVRnQXxBQ3Jtc0tsNVBtaExkN0JiVEJ1aEhMMUZLUWRfVHhmNVA3ZnMwcFNnLUJuemNOeHNxdjFlZlB4LXdTMk5LdklXekZDMnZDb1BGbEducE9ZRzB2QkJVUmtlc29jWTFwbjF6aVk1d2pFTEw2eWpiZHgwcG1NWDhuNA&q=https%3A%2F%2Fwww.isrctn.com%2FISRCTN17592593&v=D-YV9GR6peAhttps://www.isrctn.com/ISRCTN17592593 [https://www.isrctn.com/ISRCTN17592593] * Get in touch with the research team: whh-tr.researchanddevelopment@nhs.net  [whh-tr.researchanddevelopment@nhs.net] * Watch our previous interview with Dr. Harry Horsley: https://www.youtube.com/watch?v=pq1K1zBt7Ho [https://www.youtube.com/watch?v=pq1K1zBt7Ho] * More on the science behind chronic urinary tract infection: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbFJQb3NZUmp5cThNcWZuNVFsb3VuVHF5cVFrZ3xBQ3Jtc0tsNy1iVHZJWUVabmpKVEs2bm9yS2xsNVNuTERHWktJYk9NZWpkeU5rVnphSDl1cVZXelFxYkk1M3B5LW92Uk94ZW0zUG55LUxNZkhWVWRrdmlCQ0F0SDNXaE52SXpOZVF5MjlyTGpONHRDQ0ZfY3pwQQ&q=https%3A%2F%2Fliveutifree.com%2Fchronic-urinary-tract-infection&v=D-YV9GR6peAhttps://liveutifree.com/chronic-urinary-tract-infection/ [https://liveutifree.com/chronic-urinary-tract-infection/]

Chronic UTI Prevention, Bladder Tea, & D-Mannose | Julia Anditsch with Live UTI Free (LUF)

What if your bladder isn’t working against you, but trying to tell you something? In this episode of the Live UTI Free podcast, host Melissa Kramer sits down with Julia Anditsch, founder of Die Blase (German for “The Bladder”), an international bladder health platform based in Germany and Austria, and creator of Die Blase To Go, the first ready-to-drink bottled bladder tea. Together, Julia and Melissa get into the tools, tests, and daily habits that patients in their communities are actually using to manage recurrent and chronic UTI. They cover D-mannose; lactic acid bacteria probiotics for the gut and vagina; bladder teas made with nettle, goldenrod, birch leaf, ginger, and mint; Hiprex (methenamine hippurate); and the UK ULTA study; UTI vaccines like Uromune, Uro-Vaxom, and Strovac; the importance of testing for STIs and ureaplasma alongside UTI; and the emerging research connecting the urogenital microbiome to fertility and pregnancy. Whether you’re newly diagnosed or years into a chronic UTI journey, this conversation offers real patient experience, science, and a reminder that you’re not alone. What You’ll Learn * Why standard urine dipsticks and cultures can miss infections, and what tests like vaginal swabs, PCR, and STI panels may pick up. Plus, why looking at bladder, gut, and vaginal health together can offer a more complete picture. * What alternatives and add-ons to antibiotics are being explored in the community. This includes D-mannose, probiotics, bladder teas, Hiprex (methenamine hippurate), and vaccines like Uromune, Uro-Vaxom, and Strovac. Also covered: what’s known, what’s still being researched, and how access varies by country. * Which everyday factors often come up as possible UTI triggers, including heat, cold feet, dehydration, stress, and sex. Plus, simple daily habits some people find helpful alongside their treatment plan. Resources and Links * Learn more and access related articles: liveutifree.com [http://liveutifree.com/] * Subscribe to the LUF YouTube channel [https://www.youtube.com/@LiveUTIFree] for video format

Why UTI Tests Keep Failing You And What Science Is Doing About It | Prof. Jenny Roan with Live UTI Free

If you’ve ever been told your urine test came back negative but you know something is wrong, this episode is for you. Host Melissa Kramer speaks with Professor Jenny Roan, Head of the Centre for Urological Biology at University College London (UCL), to get into the science that most people living with recurrent or chronic UTI desperately want to understand. From why the dipstick test misses so many real infections, to what’s actually happening inside the bladder wall when antibiotics stop working, Professor Roan breaks it all down in plain language, without dismissal. Professor Roan also shares details of a novel treatment her team at UCL has developed, CapFuran, a microencapsulated nitrofurantoin designed to deliver the antibiotic directly into the bladder wall to target embedded bacteria and biofilms that standard antibiotics simply can’t reach. With a potential clinical trial horizon of 2026–2027, this is the research the chronic UTI community has been waiting for. 3 Key Takeaways 1. Your negative test result doesn’t necessarily mean there’s no infection. Dilution, the wrong type of bacteria, mixed growth being discarded… There are multiple scientific reasons a real UTI can be missed. The research highlighting these inadequacies has existed for decades. 2. Chronic UTI may involve bacteria that are literally hiding inside your bladder wall. These intracellular bacteria and biofilms are dormant and largely unreachable by standard short-course antibiotics, which is why a three-day course of nitrofurantoin often isn’t enough. 3. Research into new treatments is moving forward and the patient community is part of the push. From the uro-immune vaccine to a novel encapsulated antibiotic therapy targeting embedded infection, there are promising options in development. The more patients ask questions and advocate for themselves, the harder it becomes to ignore this area of health. Resources and Links * Learn more and access related articles: https://www.liveutifree.comliveutifree.com [http://liveutifree.com] * Subscribe to the LUF YouTube channel [https://www.youtube.com/@LiveUTIFree] for video format * Connect with Professor Jenny Roan via UCL [https://profiles.ucl.ac.uk/6235-jennifer-rohn] or LinkedIn [https://uk.linkedin.com/in/jennifer-rohn-9498661]